UroGen Pharma (URGN) News Today $11.45 +0.29 (+2.60%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period UroGen Pharma: Choice Based On Near-Term High-Value PDUFANovember 13, 2024 | seekingalpha.comUroGen Pharma (NASDAQ:URGN) vs. Virpax Pharmaceuticals (NASDAQ:VRPX) Critical ReviewNovember 13, 2024 | americanbankingnews.comUroGen Pharma Reports 2024 Third Quarter Financial Results and Business HighlightsURGN Pharmaceuticals, a leading biotech company focused on urothelial and specialty cancers, disclosed its latest financial outcomes for the third quarter ended SeptembNovember 13, 2024 | americanbankingnews.comHC Wainwright Forecasts Higher Earnings for UroGen PharmaNovember 12, 2024 | americanbankingnews.comUroGen Pharma FY2024 EPS Estimate Lifted by HC WainwrightUroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - Equities researchers at HC Wainwright increased their FY2024 EPS estimates for UroGen Pharma in a report issued on Thursday, November 7th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($3.01) per share for tNovember 11, 2024 | marketbeat.comUroGen Pharma Ltd. (NASDAQ:URGN) Just Reported, And Analysts Assigned A US$39.93 Price TargetNovember 10, 2024 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | msn.comUroGen Pharma Reports Q3 Results and Drug ProgressNovember 8, 2024 | markets.businessinsider.comUroGen Pharma Ltd (URGN) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...November 7, 2024 | finance.yahoo.comOptimistic Buy Rating for Urogen Pharma Driven by Strong Jelmyto Sales and Promising UGN-102 Approval ProspectsNovember 7, 2024 | markets.businessinsider.comUroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call TranscriptNovember 6, 2024 | seekingalpha.comUroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025November 6, 2024 | finance.yahoo.comUroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation ConferenceNovember 5, 2024 | finance.yahoo.comRice Hall James & Associates LLC Acquires 199,110 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)Rice Hall James & Associates LLC increased its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 273.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 271,897 shares of the company's stock afterNovember 2, 2024 | marketbeat.comUroGen Pharma (URGN) to Release Quarterly Earnings on WednesdayUroGen Pharma (NASDAQ:URGN) will be releasing earnings before the market opens on Wednesday, November 6, Zacks reports.October 31, 2024 | marketbeat.comInvestors in UroGen Pharma (NASDAQ:URGN) have unfortunately lost 42% over the last five yearsOctober 20, 2024 | finance.yahoo.comTD Cowen Keeps Their Buy Rating on Urogen Pharma (URGN)October 16, 2024 | markets.businessinsider.comUrogen Pharma (URGN) Receives a Buy from OppenheimerOctober 16, 2024 | markets.businessinsider.comUroGen Announces FDA Acceptance of its New Drug Application for UGN-102October 16, 2024 | businesswire.comEF Hutton Initiates Coverage of UroGen Pharma (URGN) with Buy RecommendationOctober 16, 2024 | msn.comUroGen Pharma (NASDAQ:URGN) Receives "Outperform" Rating from OppenheimerOppenheimer reaffirmed an "outperform" rating and set a $40.00 target price on shares of UroGen Pharma in a research note on Wednesday.October 16, 2024 | marketbeat.comWesbanco Bank Inc. Purchases New Stake in UroGen Pharma Ltd. (NASDAQ:URGN)Wesbanco Bank Inc. acquired a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 74,400 shares of the company's stock, valued at approximately $945,October 16, 2024 | marketbeat.comUroGen Pharma's (URGN) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and set a $60.00 price target on shares of UroGen Pharma in a research report on Tuesday.October 15, 2024 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Lifted to Strong-Buy at EF Hutton Acquisition Co. IEF Hutton Acquisition Co. I upgraded UroGen Pharma to a "strong-buy" rating in a report on Monday.October 15, 2024 | marketbeat.comBuy Rating for UroGen Pharma Amidst Key Executive Appointment and Promising Drug PipelineOctober 14, 2024 | markets.businessinsider.comUroGen Pharma Appoints Chris Degnan To Succeed Don Kim As CFOOctober 9, 2024 | markets.businessinsider.comUroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...October 9, 2024 | finance.yahoo.comMarshall Wace LLP Buys Shares of 42,841 UroGen Pharma Ltd. (NASDAQ:URGN)Marshall Wace LLP purchased a new stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 42,841 shares of the company's stock, valued at approximately $7October 9, 2024 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Stock, Short Interest ReportOctober 6, 2024 | benzinga.comUroGen Pharma (NASDAQ:URGN) Stock, Insider Trading ActivityOctober 5, 2024 | benzinga.comMillennium Management LLC Grows Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)Millennium Management LLC grew its stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 2,672.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,160,899 shares of the company'sOctober 5, 2024 | marketbeat.comUroGen Pharma (NASDAQ:URGN) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of UroGen Pharma in a research report on Thursday.October 3, 2024 | marketbeat.comPoint72 Asset Management L.P. Purchases 1,337,257 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)Point72 Asset Management L.P. raised its position in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 120.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,449,277 shares of the company's stock after purchasing an addiSeptember 26, 2024 | marketbeat.comGreat Point Partners LLC Increases Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)Great Point Partners LLC raised its stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 10.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,906,259 shares of the company's stock after purchasing aSeptember 24, 2024 | marketbeat.comUroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy NowSeptember 23, 2024 | msn.comUroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR StockSeptember 23, 2024 | msn.comOppenheimer Remains a Buy on Urogen Pharma (URGN)September 18, 2024 | markets.businessinsider.comUroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041September 16, 2024 | stockhouse.comMark Schoenberg Sells 859 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) StockSeptember 13, 2024 | insidertrades.comJason Drew Smith Sells 1,521 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) StockSeptember 13, 2024 | insidertrades.comCowen AND Company LLC Buys 472,893 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)Cowen AND Company LLC grew its stake in UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) by 29.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,099,482 shares of the company's stock after acquiring an aSeptember 9, 2024 | marketbeat.comUroGen Pharma's JELMYTO And UGN-102: A Strong Buy In The Urological Cancer SectorAugust 29, 2024 | seekingalpha.comUroGen Pharma: There Is Some Potential HereAugust 28, 2024 | seekingalpha.comUroGen Pharma (NASDAQ:URGN) Earns Buy Rating from Analysts at GuggenheimGuggenheim initiated coverage on shares of UroGen Pharma in a research report on Thursday. They set a "buy" rating and a $40.00 price objective for the company.August 22, 2024 | marketbeat.comURGN Sep 2024 20.000 call (URGN240920C00020000)August 18, 2024 | finance.yahoo.comUroGen Pharma Ltd. (NASDAQ:URGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$43.88August 16, 2024 | finance.yahoo.comQ3 2024 EPS Estimates for UroGen Pharma Ltd. Lowered by HC Wainwright (NASDAQ:URGN)UroGen Pharma Ltd. (NASDAQ:URGN - Free Report) - Equities research analysts at HC Wainwright cut their Q3 2024 EPS estimates for shares of UroGen Pharma in a report released on Wednesday, August 14th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.80)August 16, 2024 | marketbeat.comBuy Rating Affirmed for UroGen Pharma on Strong UGN-102 Prospects and Solid Market Expansion PotentialAugust 15, 2024 | markets.businessinsider.comUroGen Pharma Ltd. (NASDAQ:URGN) Q2 2024 Earnings Call TranscriptAugust 14, 2024 | msn.comUroGen Pharma (NASDAQ:URGN) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $60.00 target price on shares of UroGen Pharma in a research report on Wednesday.August 14, 2024 | marketbeat.com Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address JD Vance Predicts: Wall Street vs. Trump & Your Money (Ad)Trump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback. Get your free guide NOW before it's too late. URGN Media Mentions By Week URGN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. URGN News Sentiment▼-0.550.45▲Average Medical News Sentiment URGN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. URGN Articles This Week▼12▲URGN Articles Average Week Get UroGen Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Puma Biotechnology News Today Akebia Therapeutics News Today RAPT Therapeutics News Today Marinus Pharmaceuticals News Today Avadel Pharmaceuticals News Today Zymeworks News Today Septerna News Today Cogent Biosciences News Today Bicara Therapeutics News Today Bicycle Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:URGN) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding UroGen Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share UroGen Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free URGN Stock Alerts